“…Open trials of DBT‐A have provided some initial support for treating a number of presenting issues within several treatment settings. Researchers have reported statistically significant reductions of psychiatric symptoms, including anxiety and depression (Beckstead, Lambert, DuBose, & Linehan, ; Del Conte, Lenz, & Hollenbaugh, ), suicidal ideation (Hjalmarsson, Kaver, Perseius, Cederberg, & Ghaderi, ), and disordered eating (Salbach‐Andrae, Bohnekamp, Pfeiffer, Lehmkuhl, & Miller, ), with Cohen's d effect sizes ranging from medium to large. These studies have been integral in demonstrating important aspects of DBT‐A, such as the feasibility of transitioning treatment milieus with considerable fidelity and desired treatment effect (Katz, Cox, Gunasekara, & Miller, ; Perepletchikova et al, ), and also understanding the treatment components that function as mechanisms of therapeutic change (Lenz, Del Conte, Hollenbaugh, & Callendar, ).…”